Skip to main content
Equibles
ELV logo

ELV · Elevance Health, Inc.

Track ELV — free

Use ELV with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$407.53 +1.69 (+0.42%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$88.01B
Shares
216.87M

ELV metrics

96 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$405.84
Market cap
$88.01B

Price action

19 metrics
Price change (1W)
+1.0%
Price change (30D)
+5.3%
Price change (3M)
+3.6%
Price change (6M)
+41.9%
Price change (YTD)
+15.0%
Price change (1Y)
+26.5%
Trailing year
Price change (5Y)
+9.1%
52-week high
$426.79
52-week low
$280.74
Change from 52-week high
-5.6%
Change from 52-week low
+43.6%
Annualized volatility
35.3%
Beta
0.3
RSI (14D)
55.7
Price vs SMA 50
+2.0%
Price vs SMA 200
+12.6%
Avg volume (3M)
1.41M
Relative volume
0.8
Average dollar volume
$557.04M

Company

3 metrics
Sector
Healthcare
Industry
Healthcare Plans
Shares outstanding
216.87M

Valuation

12 metrics
P / E (TTM)
17.8
Trailing earnings · reciprocal yield 5.6%
PEG ratio
—
EV / revenue
0.5×
reciprocal yield 185.6%
EV / EBITDA
15.6×
reciprocal yield 6.4%
EV / EBIT
19.9×
reciprocal yield 5.0%
P / sales
0.4×
reciprocal yield 229.8%
P / book
2.0
reciprocal yield 51.3%
FCF yield
7.2%
TTM · current market cap
Buyback yield
3.1%
P / FCF
13.9
reciprocal yield 7.2%
P / operating cash flow
11.7
reciprocal yield 8.5%
Earnings yield
5.7%

Historical valuation

8 metrics
P / E historical average (3Y)
16.4×
reciprocal yield 6.1%
P / E historical average (5Y)
17.6×
reciprocal yield 5.7%
EV / revenue historical average (3Y)
0.6×
reciprocal yield 155.1%
EV / revenue historical average (5Y)
0.7×
reciprocal yield 136.4%
EV / EBIT historical average (3Y)
14.9×
reciprocal yield 6.7%
EV / EBIT historical average (5Y)
15.7×
reciprocal yield 6.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.7%
Trailing 12 months
Payout ratio
30.3%
Shareholder yield
4.8%
Dividend / share (TTM)
$6.86
Dividend growth YoY
+2.7%
Dividend growth streak
5
Last ex-dividend
2026-06-10

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-15

Profitability

9 metrics
Gross margin
89.1%
Operating margin
2.7%
Trailing 12 months
Net margin
2.5%
Gross profit (TTM)
—
Operating profit (TTM)
$5.45B
Net income (TTM)
$4.96B
Trailing 12 months
Diluted EPS (TTM)
$22.59
FCF margin
3.1%
Effective tax rate
15.6%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$90.45

Growth

11 metrics
Revenue growth YoY
+1.4%
Year over year
Net income growth YoY
-16.1%
Revenue (TTM)
$201.11B
Trailing 12 months
EPS growth YoY
-13.1%
Shares change YoY
-3.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+8.3%
Revenue CAGR (5Y)
+10.3%
EPS CAGR (3Y)
+1.3%
EPS CAGR (5Y)
+7.0%
FCF CAGR (3Y)
-24.1%
FCF CAGR (5Y)
-20.0%

Quality

14 metrics
Return on equity
11.1%
Return on assets
3.9%
Debt / equity
0.7
Current ratio
1.5
EBITDA (TTM)
$6.97B
Free cash flow (TTM)
$6.29B
Quick ratio
1.5
Interest coverage
3.8
Net debt / EBITDA
3.0
Return on invested capital
7.0%
Trailing 12 months
Net cash
−$20.81B
Latest balance sheet
Cash & equivalents
$10.23B
Total assets
$126.44B
Total debt
$31.04B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$7.46B
Capital expenditures (TTM)
$1.18B
R&D (TTM)
—
SG&A (TTM)
$22.56B
Stock compensation (TTM)
$244.00M
R&D / revenue
—
Stock compensation / revenue
0.1%

Ownership (13F)

3 metrics
13F filers
1,618
13F filer change QoQ
+144
Institutional ownership
92.8%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.16M
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1156039 CUSIP 036752103 13F (30d) 984 filings 939 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)